The microflora in the gastrointestinal tract of broiler chickens influences digestion, health, and wellbeing. Analysis of chicken gut microflora has been mainly by culture-based methods. Studies using these techniques have been useful for identification and analysis of specific groups of bacteria, however, the use of enrichment medium precludes even relative quantitation of bacterial species. Recent advances in ribosomal DNA-based molecular techniques make it possible to identify different bacterial populations in environmental samples without cultivation. In this study, the intestinal microflora was examined using 16S ribosomal DNA (rDNA) targeted probes from bacterial DNA isolated from intestinal and cecal contents of chickens at 4, 14, and 25 d of age. The ribosomal gene sequence was amplified using PCR with universal primers to determine total bacterial DNA and specific primers directed at 6 bacterial species: Lactobacillus, Bifidobacterium, Salmonella, Campylobacter, Escherichia coli, and Clostridium. The use of universal primers extends these methods to allow determination of relative proportions of different bacterial species. The results indicated that in young chicks the major species present in the small intestines and ceca was Lactobacilli, with a Bifidobacteria population becoming more dominant in the ceca at older age. Clostridium was detected in some segments of the small intestine in young chicks. In older chickens, Salmonella, Campylobacter, and E. coli species were found in the ceca. This study has demonstrated the use of molecular techniques for determining relative proportions of bacterial species and monitoring pathogens in the chick gastrointestinal tract.
The mucous layer that covers the intestinal absorptive surface acts as a barrier against bacterial translocation. The chicken gut contains a diverse bacterial population which interacts with the mucous layer. In this report, we studied the effect of changing the intestinal microbial populations on mucin dynamics by feeding 1-d-old chicks a control diet or that diet containing either antibiotic growth promoter (AGP) or a probiotic product for 14 d. Dietary AGP increased the proportions of Bifidobacterium species in the duodenum compared with the other groups. In AGP-fed chicks, the villous surface area was increased in the jejunum, goblet cell density was greater in the jejunum and ileum, and mucin glycoprotein levels in the duodenum were lower than in the other groups (P < 0.05). Feeding AGP increased the expression of mucin mRNA in the jejunum and ileum compared with controls. The dietary probiotic increased the proportion of Lactobacillus species in the ileum compared with the controls (P < 0.05) and significantly enlarged the goblet cell "cup" area throughout the small intestine compared with the other groups. Expression of mucin mRNA and the levels of mucin glycoprotein were greater in the jejunum of the probiotic-fed chicks compared with controls (P < 0.05). Neither the probiotic nor AGP treatments affected the thickness of the mucous adherent layer. These results indicate that both probiotic and AGP altered processes of mucin biosynthesis and/or degradation mediated via changes in the intestinal bacterial populations. These modifications in mucin dynamics influence gut function and health and may change nutrient uptake.
Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington's disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell populations, especially astrocytes and microglia. Analysis of genome-wide expression data revealed activation of the aryl hydrocarbon receptor (AhR) pathway in laquinimod-treated mice. The AhR pathway modulates the differentiation and function of several cell populations, many of which play an important role in neuroinflammation. We therefore tested the consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) using AhR knockout mice. We demonstrate that the pronounced effect of laquinimod on clinical score, CNS inflammation, and demyelination in EAE was abolished in AhR −/− mice. Furthermore, using bone marrow chimeras we show that deletion of AhR in the immune system fully abrogates, whereas deletion within the CNS partially abrogates the effect of laquinimod in EAE. These data strongly support the idea that AhR is necessary for the efficacy of laquinimod in EAE and that laquinimod may represent a first-in-class drug targeting AhR for the treatment of multiple sclerosis and other neurodegenerative diseases.aryl hydrocarbon receptor | EAE | laquinimod L aquinimod is an oral drug that is currently in late-stage clinical development for the treatment of relapsing remitting multiple sclerosis (RRMS), primary progressive MS, and Huntington's disease. Current knowledge indicates that laquinimod exerts activities both on the peripheral immune system and within the CNS. Laquinimod, at the 0.6-mg/d dose, has demonstrated efficacy in phase II and III MS clinical trials, in which it reduced relapse rate, disability progression, development of new and active MRI lesions, and brain atrophy (1-3). The clinical efficacy profile of laquinimod is characterized by a dissociation of the moderate magnitude of the effect on relapse reduction and its associated inflammatory MRI findings and the disproportionally large effect on disability progression. Such an efficacy profile in patients with RRMS may relate to a distinctive intracerebral activity potentially mediated via changes in CNS resident cell populations, potentially astrocytes and microglia.
Early intestinal development is essential for chicken embryos to fulfill their maximal growth potential. Mannan oligosaccharide (MOS) is known to improve gut morphology, function, and innate immunity; therefore, we hypothesized that its administration in the prehatch period to the sterile intestine of embryos would affect intestinal development and functionality without mediation of gut microflora. The MOS was administered by in ovo feeding procedure to embryos 3 d before hatch. the effects of MOS administration on intestinal morphology, activity of the brush-border enzymes amino peptidase (AP) and sucrase isomaltase (SI) and mRNA abundance of AP, SI, sodium-dependent glucose cotransporter 1 (SGLT1), peptide transporter 1 (PepT1), secreted mucin (MUC2), and toll-like receptors (TLR2 and TLR4) were examined and compared with saline-injected and noninjected controls. Results show that on embryonic d 20 the only parameter affected was MUC2 mRNA abundance, which exhibited a 3-fold increase in the MOS group versus controls. On day of hatch more parameters were affected: a 20 to 32% increase in villus area was found in the MOS group compared with controls; crypt depth and number of goblet cells per villus were higher by 20 and 50%, respectively, compared with the saline group; and AP and SI activities were higher by 44 and 36%, respectively, compared with the noninjected control. In addition, an increase in fold change mRNA abundance of AP, SI, and TLR4 was observed in the MOS group compared with controls. However, on d 3 posthatch, a decrease in MOS effects was noted, indicating a temporally limited effect after administration of 1 dose. In ovo administration of MOS prehatch resulted in a hatching chick with more mature enterocytes and enhanced epithelial barrier and digestive and absorptive capacity at day of hatch. Results imply that the mechanism underlying the observed changes is not mediated through gut microflora but rather involves a direct effect of MOS on intestinal cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.